Panel

Noticias Financieras

Las 10 principales exportaciones australianas a nivel mundial en 2026: el mineral de hierro lidera el auge de los recursos
ibtimeshace 83d

Las 10 principales exportaciones australianas a nivel mundial en 2026: el mineral de hierro lidera el auge de los recursos

SYDNEY – La economía exportadora de Australia en 2026 seguirá dependiendo en gran medida de sus vastos recursos naturales, con el mineral de hierro, los productos energéticos y el oro dominando el comercio del país mientras la demanda global de Asia continúa generando miles de millones en ingresos a pesar de las fluctuaciones de los precios y las incertidumbres geopolíticas.

#COMMODITIES#ECONOMY
Nano Labs anuncia resultados financieros del segundo semestre de 2025
benzingahace 83d

Nano Labs anuncia resultados financieros del segundo semestre de 2025

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <p>HANGZHOU, China, March 30, 2026 (GLOBE NEWSWIRE) -- Nano Labs Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/NA" rel="nofollow">NA</a>) ("we," the "Company" or "Nano Labs"), a leading Web 3.0 infrastructure and product solution provider and crypto treasury company today announced its unaudited financial results as of December 31, 2025 and for the six months ended December 31, 2025.</p> <p align="justify"><strong>Second Half of 2025 Financial Summary</strong></p> <ul> <li>Net revenue increased by 18.1% to RMB18.7 million (US$2.7 million) for the second half of 2025, from RMB15.9 million in the same period of 2024.</li> <li>Gross loss was RMB29.1 million (US$4.1 million) for the second half of 2025, compared to a gross profit of RMB11.6 million in the same period of 2024.</li> <li>Gain on change in fair value of cryptocurrencies was RMB130.0 million (US$18.5 million) for the second half of 2025, compared to a loss of RMB15.7 million in the same period of 2024.</li> <li>Profit from operations was RMB60.8 million (US$8.7 million) for the second half of 2025, compared to a loss of RMB55.6 million in the same period of 2024.</li> <li>Net income was RMB137.7 million (US$19.6 million) for the second half of 2025, compared to a net loss of RMB 60.4 million in the same period of 2024.</li> <li>Net income per share (both basic and diluted) was approximately RMB6.2 (US$0.9) for the second half of 2025, compared to a net loss per share (both basic and diluted) of approximately RMB6.0 in the same period of 2024.<br /><br /></li> </ul> <p align="justify">Mr. Jianping Kong, Chairman and Chief Executive Officer of the Company, commented: "2025 witnessed vigorous development in the Web 3.0 industry. With the continuous improvement of the global crypto market environment, including the enhancement of crypto asset infrastructure and rising market participation, the crypto market and Web 3.0-related sectors embraced a new phase of growth and opportunities.</p> <p align="justify">Following a comprehensive and meticulous internal assessment of BNB's strategic value and long-term prospects, we decided to take the lead in launching and continuously advancing the buildout of a BNB reserve. As of December 31, 2025, we held a total of 126,662 BNBs and a receivable for 3,338 BNBs collateral. By steadily increasing the BNB holdings, we have not only optimized our crypto asset allocation but also created favorable conditions for future business expansion and ecological collaboration.</p> <p align="justify">In terms of capital operations, we successfully completed two rounds of financing in 2025, which provided strong support for the Company's strategic transformation, the expansion of our crypto asset reserves, and the exploration of new business directions.</p> <p align="justify">In March 2026, we officially launched our new-generation product — iPollo ClawPC A1 Mini, designed to support the Open Claw AI Agent system. Subsequently, we plan to introduce the Claw OS system and more hardware products to further extend the full-chain ecological services for AI Agents.</p> <p align="justify">Meanwhile, to further enhance shareholder value and demonstrate the management's confidence in the Company's long-term development, we announced a share repurchase program of up to US$25.0 million in October 2025. This program has commenced and is expected to be implemented steadily over the long term.</p> <p align="justify">Looking ahead, we will continue to closely monitor emerging industry trends and market dynamics. While maintaining stable operations, we will further advance our crypto asset strategic reserve and pursue broader industrial opportunities in the AI Agent ecosystem."</p> <p align="justify">Mr. Bing Chen, Chief Financial Officer of the Company, added: "For the second half of 2025, our net revenue increased by 18.1% from RMB15.9 million to RMB18.7 million (US$2.7 million). In addition, we successfully turned to a net income of RMB137.7 million (US$19.6 million) for the six months ended December 31, 2025, compared to a net loss of RMB60.4 million in the same period of 2024. Adhering to the principles of long-termism and prudent decision-making, our management will continue to monitor and capture emerging opportunities arising in the transformation from Web 3.0 to Web 4.0, with the goal of creating sustainable long-term value for the Company and all shareholders."</p> <p align="justify"><strong>Second Half of 2025 Financial Results</strong></p> <p align="justify"><strong><em>Net Revenues</em></strong></p> <p align="justify">Net revenue was RMB18.7 million (US$2.7 million) for the second half of 2025, compared to RMB15.9 million for the same period of 2024. The increase was primarily due to the increase in sales volume of iPollo V Series.</p> <p align="justify"><strong><em>Cost of Revenues</em></strong></p> <p align="justify">Cost of revenues was RMB47.8 million (US$6.8 million) for the second half of 2025, compared to RMB4.3 million for the same period of 2024. The change was mainly due to the write-downs of inventories and value-added tax recoverable.</p> <p align="justify"><strong><em>Operating Income (Expenses)</em></strong></p> <p align="justify">Total operating income increased by 233.9% to RMB89.9 million (US$12.8 million) for the second half of 2025, compared to a total operating expenses of RMB67.1 million for the same period of 2024.</p> <ul> <li>Selling and marketing expenses decreased by 56.2% to RMB2.1 million (US$0.3 million) for the second half of 2025, from RMB4.8 million for the same period of 2024. The decrease in selling and marketing expenses was primarily due to the decrease in employee salary expenses.</li> <li>General and administrative expenses increased by 30.3% to RMB33.1 million (US$4.7 million) for the second half of 2025, from RMB25.4 million for the same period of 2024. The increase in general and administrative expenses was primarily due to the increase in professional services fees.</li> <li>Research and development expenses decreased by 76.9% to RMB4.9 million (US$0.7 million) for the second half of 2025, from RMB21.2 million for the same period of 2024. The decrease in research and development expenses was primarily due to the decrease in salary expenses, material fees, and equipment fees.</li> <li>Change in fair value of cryptocurrencies was a gain of RMB130.0 million (US$18.5 million) for the second half of 2025, compared to a loss of RMB15.7 million for the same period of 2024. The increase in gain from change in fair value of cryptocurrencies was primarily due to the increased BNB price during the second half of 2025.<br /><br /></li> </ul> <p align="justify"><strong><em>Profit (Loss) from Operations</em></strong></p> <p align="justify">Profit from operations was RMB60.8 million (US$8.7 million) for the second half of 2025, compared to loss from operations of RMB55.6 million for the same period of 2024.</p> <p align="justify"><strong><em>Finance Expenses</em></strong></p> <p align="justify">Finance expenses was RMB0.3 million (US$0.05 million) for the second half of 2025, compared to RMB2.0 million for the same period of 2024.</p> <p align="justify"><strong><em>Interest Expenses</em></strong></p> <p align="justify">Interest expenses was RMB11.7 million (US$1.7 million) for the second half of 2025, compared to RMB4.9 million for the same period of 2024. The change was due to the interest paid for the borrowings denominated in Bitcoin during the second half of 2025.</p> <p align="justify"><strong><em>Change in Fair Value of Borrowings Denominated in Cryptocurrencies</em></strong></p> <p align="justify">Change in fair value of borrowings denominated in cryptocurrencies was a gain of RMB60.5 million (US$8.6 million) for the second half of 2025, compared to nil for the same period of 2024. The change was due to the borrowings denominated in Bitcoin in 2025, which was measured at fair value and repaid before December 31, 2025.</p> <p align="justify"><strong><em>Other Income</em></strong></p> <p align="justify">Other income was RMB38.2 million (US$5.4 million) for the second half of 2025, compared to RMB1.7 million for the same period of 2024. The change was due to the Binance Launchpool and Airdrop income for BNB holders and income from crypto investment products.</p> <p align="justify"><strong><em>Other Expenses</em></strong></p> <p align="justify">Other expenses was RMB9.9 million (US$1.4 million) for the second half of 2025, compared to nil for the same period of 2024. The change was due to the loss from change in fair value of short-term investments during the second half of 2025.</p> <p align="justify"><strong><em>Net Income (Loss)</em></strong></p> <p align="justify">Net income was RMB137.7 million (US$19.6 million) for the second half of 2025, compared to a net loss of RMB60.4 million in the same period of 2024.</p> <p align="justify"><strong><em>Basic and Diluted Earnings or Loss Per Ordinary Share attributable to Nano Labs Ltd</em></strong></p> <p align="justify">Basic and diluted earnings per share was approximately RMB6.2 (US$0.9) for the second half of 2025, compared to basic and diluted loss per share of approximately RMB6.0 for the same period of 2024.</p> <p align="justify"><strong><em>Cash and Cash Equivalents</em></strong></p> <p align="justify">As of December 31, 2025, the Company had cash and cash equivalents of RMB8.5 million (US$1.2 million), compared to RMB32.4 million as of December 31, 2024.</p> <p align="justify"><strong>Exchange Rate</strong></p> <p align="justify">This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB7.0288 to US$1.00, the central parity rate on December 31, 2025 published by the People's Bank of China.</p> <p align="justify"><strong>Non-GAAP Financial Measures</strong></p> <p align="justify">In evaluating our business, we consider and use adjusted net income/(loss) as an additional non-GAAP measure to review and assess our operating performance. The presentation of the non-GAAP financial measure is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with U.S. GAAP. We define adjusted net income/(loss) as net income/(loss) excluding share-based compensation expense.</p> <p align="justify">We present the non-GAAP financial measure because they are used by our management to evaluate our operating performance and formulate business plans. Non-GAAP financial measures enable our management to assess our operating results without considering the impact of non-cash charges and non-operating items. We also believe that the use of the non-GAAP measure facilitates investors' assessment of our operating performance.</p> <p align="justify">The non-GAAP financial measure is not defined under U.S. GAAP and is not presented in accordance with U.S. GAAP. The non-GAAP financial measure has limitations as analytical tools. One of the key limitations of using the non-GAAP financial measure is that they do not reflect all items of income and expense that affect our operations. Share-based compensation expenses have been and may continue to be incurred in our business and are not reflected in the presentation of adjusted net income/(loss). Further, the non-GAAP measure may differ from the non-GAAP information used by other companies, including peer companies, and therefore their comparability may be limited.</p> <p align="justify"><strong>Conference Call</strong></p> <p align="justify">The Company will host an earnings conference call to discuss its financial results at 8:30 am U.S. Eastern Time (8:30 pm Beijing Time) on March 30, 2026.</p> <p align="justify">For participants who wish to join the call, please access the link provided below to complete the online registration process.</p> <p align="justify">Registration Link: <a href="https://www.globenewswire.com/Tracker?data=EHNFtPyaorOHZ98_fDxCj2gLCtmjgMHpbWxTsK5QI0X9SPoBbjpq-Vz28iLlVtZr135pwcJxVzjod_C30pGpp0Cho8Cc8Idb_PM1-4tpkWJw_3YPz1K8uUdiocW-bkbBaYQBaQriTGTnOCmSfIX3ofIF7Tpkx8q4ptoJjKrYgi8nDzH3zVi98Kqf-A6ogwFd" rel="nofollow" target="_blank" rel="nofollow">https://s1.c-conf.com/diamondpass/10053968-bdhi7v.html</a></p> <p align="justify">Upon registration, participants will receive the dial-in number and unique PIN, which can be used to join the conference call. If participants register and forget their PIN or lose their registration confirmation email, they may simply re-register and receive a new PIN. All participants are encouraged to dial in 15 minutes prior to the start time.</p> <p align="justify">A live and archived webcast of the conference call will be accessible on the Company's investor relations website at: <a href="https://www.globenewswire.com/Tracker?data=EHNFtPyaorOHZ98_fDxCj7lXJE_K1fH7O1kW1y83mDmIwkBit1YBrwY2Kr1VUFu6s8rTj_mlzFlzqFvJ9dT6pVn-OoUgA6qqVT7LmSyyYuQ=" rel="nofollow" target="_blank" rel="nofollow">https://ir.nano.cn/</a>.</p> <p align="justify">A telephone replay of the call will be available until 6 April 2026 via the following dial-in details:</p> <p align="justify"><strong><u>Dial-in Numbers:</u></strong></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"> <tr> <td style="max-width:30%; width:30%; min-width:30%;;vertical-align: middle; text-align: left; padding-left: 25.0px; vertical-align: top ; ">US/Canada:</td> <td style="max-width:70%; width:70%; min-width:70%;;text-align: justify ; vertical-align: middle; vertical-align: top ; ">1855 883 1031</td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 25.0px; vertical-align: top ; "> </td> <td style="text-align: justify ; vertical-align: middle; vertical-align: top ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 25.0px; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Hong Kong:</td> <td style="text-align: justify ; vertical-align: middle; vertical-align: top ; ">800 930 639</td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 25.0px; text-align: justify ; vertical-align: middle; vertical-align: top ; "> </td> <td style="text-align: justify ; vertical-align: middle; vertical-align: top ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 25.0px; text-align: justify ; vertical-align: middle; vertical-align: top ; ">China:</td> <td style="text-align: justify ; vertical-align: middle; vertical-align: top ; ">400 1209 216</td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 25.0px; text-align: justify ; vertical-align: middle; vertical-align: top ; "> </td> <td style="text-align: justify ; vertical-align: middle; vertical-align: top ; "> </td> </tr> <tr> <td style="vertical-align: middle; text-align: left; padding-left: 25.0px; text-align: justify ; vertical-align: middle; vertical-align: top ; ">Replay PIN:</td> <td style="text-align: justify ; vertical-align: middle; vertical-align: top ; ">10053968</td> </tr> <tr> <td> </td> <td> </td> </tr> </table> <p align="justify"><strong>About Nano Labs Ltd</strong></p> <p align="justify">Nano Labs Ltd is a leading Web 3.0 infrastructure and product solution provider, and crypto treasury company. Nano Labs is committed to the development of high throughput computing ("HTC") chips and high performance computing ("HPC") chips. Nano Labs has built a comprehensive flow processing unit ("FPU") architecture which offers solution that integrates the features of both HTC and HPC. In addition, Nano Labs has actively positioned itself in the crypto assets space, adopting BNB as its primary reserve asset. It has reserved in mainstream crypto currency, BNB, and established an integrated platform covering multiple business verticals, including HTC solutions, HPC solutions and iPollo Claw*. For more information, please visit the Company's website at: <a href="https://www.globenewswire.com/Tracker?data=6_NFE9SV42-mS4YuUehB60LLrz78D_FIt5AWzXr_pSbl8WGc-KhcXWKuV58-nVP7heDyaWwCKBQJwvf-sr9V1A==" rel="nofollow" target="_blank" rel="nofollow">ir.nano.cn</a>.</p> <p align="justify">*According to an industry report prepared by Frost & Sullivan.</p> <p align="justify"><strong>Forward-Looking Statements</strong></p> <p align="justify">This report contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, the Company's plan to appeal the Staff's determination, which can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond the Company's control, which may cause the Company's actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.</p> <p align="justify"><strong>For investor and media inquiries, please contact:</strong></p> <p align="justify"><strong>Nano Labs Ltd</strong><br />Email: <a href="https://www.globenewswire.com/Tracker?data=dY2MsplSL_SSW_viu7MYLHLCqq9vEX_A3tjSpKCsjiwMkxPhKzKc4gQCR1Nltp3G-qa91DPPxbn_YZR5fOp1MA==" rel="nofollow" target="_blank" rel="nofollow"> [email protected] </a></p> <p align="justify"><strong>Ascent Investor Relations LLC</strong><br />Tina Xiao<br />Phone: +1-646-932-7242<br />Email: <a href="https://www.globenewswire.com/Tracker?data=h8cssbKD8e6i9LapsB7Wvd8hs4wmn5bOXkBgHiuOXr6A-HF_y9y-By0e_oWIArzujOX-THtx8W6ZyaGgnP0UaSECDkqRFrZUPK_ieCi0OfDwSnmuFPvs6b-FFVcBmiSo" rel="nofollow" target="_blank" rel="nofollow"> [email protected] </a></p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"> <tr> <td colspan="10" style="width:100%;;text-align: center ; vertical-align: middle; "><strong>Consolidated Balance Sheets<br />(Unaudited)<br /></strong></td> </tr> <tr> <td colspan="10" style="width:100%;"> </td> </tr> <tr> <td style="width:60.5368%;;text-align: center ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="2" style="width:11.0338%;;text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>As of<br />December<br />31,</strong></td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td colspan="5" style="width:24.5527%;;text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>As of December 31,</strong></td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;text-align: center ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="2" style="width:11.0338%;;border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>2024</strong></td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td colspan="5" style="width:24.5527%;;border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>2025</strong></td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;text-align: center ; vertical-align: middle; vertical-align: bottom ; "> </td> <td colspan="2" style="width:11.0338%;;border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>RMB</strong></td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td colspan="2" style="width:11.5308%;;border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>RMB</strong></td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td colspan="2" style="width:11.0338%;;border-bottom: solid black 1pt ; text-align: center ; vertical-align: middle; vertical-align: bottom ; "><strong>US$</strong></td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;text-align: justify ; vertical-align: middle; vertical-align: bottom ; "><strong>ASSETS</strong></td> <td colspan="2" style="width:11.0338%;;text-align: center ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td colspan="2" style="width:11.5308%;;vertical-align: bottom ; "> </td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td colspan="2" style="width:11.0338%;;vertical-align: bottom ; "> </td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="max-width:61%; width:60.5368%; min-width:61%;;text-align: justify ; vertical-align: middle; vertical-align: bottom ; "><strong>Current assets:</strong></td> <td style="max-width:1%; width:0.994036%; min-width:1%;;vertical-align: bottom ; "> </td> <td style="max-width:10%; width:10.0398%; min-width:10%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:2%; width:1.98807%; min-width:2%;;vertical-align: bottom ; "> </td> <td style="max-width:1%; width:0.994036%; min-width:1%;;vertical-align: bottom ; "> </td> <td style="max-width:10%; width:10.5368%; min-width:10%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:2%; width:1.98807%; min-width:2%;;vertical-align: bottom ; "> </td> <td style="max-width:1%; width:0.994036%; min-width:1%;;vertical-align: bottom ; "> </td> <td style="max-width:10%; width:10.0398%; min-width:10%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; "> </td> <td style="max-width:2%; width:1.88867%; min-width:2%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;vertical-align: middle; text-align: left; padding-left: 10.0px; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Cash and cash equivalents</td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">32,431,081</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.5368%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">8,502,357</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">1,209,646</td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;vertical-align: middle; text-align: left; padding-left: 10.0px; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Restricted cash</td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">418,722</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.5368%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">1,347,795</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">191,753</td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;vertical-align: middle; text-align: left; padding-left: 10.0px; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Accounts receivable, net</td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">572,803</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.5368%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">281,446</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">40,042</td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;vertical-align: middle; text-align: left; padding-left: 10.0px; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Inventories, net</td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">29,866,418</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.5368%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">13,693,374</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">1,948,181</td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;vertical-align: middle; text-align: left; padding-left: 10.0px; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Prepayments</td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">4,606,066</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.5368%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">7,567,871</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">1,076,695</td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;vertical-align: middle; text-align: left; padding-left: 10.0px; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Short-term investments</td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">-</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.5368%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">26,214,992</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">3,729,654</td> <td style="width:1.88867%;;vertical-align: bottom ; "> </td> </tr> <tr> <td style="width:60.5368%;;vertical-align: middle; text-align: left; padding-left: 10.0px; text-align: justify ; vertical-align: middle; vertical-align: bottom ; ">Receivable for cryptocurrencies collateral</td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.0398%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">-</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: bottom ; "> </td> <td style="width:10.5368%;;text-align: right ; vertical-align: middle; vertical-align: bottom ; ">20,387,316</td> <td style="width:1.98807%;;vertical-align: bottom ; "> </td> <td style="width:0.994036%;;vertical-align: ...</tr></table><p><a href=https://www.benzinga.com/pressreleases/26/03/g51535439/nano-labs-announces-second-half-of-2025-financial-results?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel alt=Nano Labs Announces Second Half of 2025 Financial Results>Full story available on Benzinga.com</a></p>

#STOCKS#ECONOMY
PAVmed proporciona actualización comercial e informa los resultados financieros del cuarto trimestre y del año completo 2025
benzingahace 83d

PAVmed proporciona actualización comercial e informa los resultados financieros del cuarto trimestre y del año completo 2025

PAVmed fortaleció su estructura de capital y relanzó su cartera de dispositivos médicos bajo un nuevo liderazgo Veris Health avanzó en la asociación estratégica con OSU y avanzó con el monitor fisiológico implantable hacia la presentación a la FDA Lucid Diagnostics amplió el acceso al sistema de atención médica EsoGuard y la base de evidencia clínica La conferencia telefónica y la transmisión por Internet se llevarán a cabo hoy, 30 de marzo, a las 8:30 a. m. EST NUEVA YORK, 30 de marzo de 2026 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" o el "Compañía"), una compañía diversificada de tecnología médica en etapa comercial, que opera en los sectores de dispositivos médicos, diagnóstico y salud digital, proporcionó hoy una actualización comercial para la Compañía y sus subsidiarias, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") y Veris Health Inc. ("Veris"), e informó los resultados financieros para el cuarto trimestre y el año finalizado el 31 de diciembre de 2025. Conferencia telefónica y transmisión web La transmisión web se llevará a cabo el lunes 30 de marzo. de 2026, a las 8:30 a. m. y está disponible en la sección de relaciones con inversionistas del sitio web de la Compañía en pavmed.com. Alternativamente, para acceder a la conferencia telefónica por teléfono, las personas que llaman desde EE. UU. deben marcar el 1-800-836-8184 y los oyentes internacionales deben marcar el 1-646-357-8785. Todos los oyentes deben proporcionar al operador el nombre de la conferencia telefónica "PAVmed Business Update" para unirse. Una vez finalizada la conferencia telefónica, habrá una repetición disponible durante 30 días en la sección de relaciones con inversionistas del sitio web de la Compañía en pavmed.com. Aspectos destacados de la actualización empresarial "Durante los últimos dos años, hemos emprendido una serie de acciones deliberadas y sistemáticas para arreglar la estructura de capital heredada de PAVmed y fortalecer su balance", dijo Lishan Aklog, M.D., presidente y director ejecutivo de PAVmed. "Este proceso ahora está completo y creemos que PAVmed está excepcionalmente bien posicionada para ejecutar su misión fundacional: operar como una compañía comercial diversificada de ciencias biológicas de alto crecimiento con múltiples subsidiarias financiadas de forma independiente que operan bajo un modelo de servicios compartidos. Veris ahora está en la fase comercial de su compromiso estratégico con OSU-The James mientras avanza su monitor fisiológico implantable hacia la presentación a la FDA. Lucid continúa manteniendo una base comercial sólida a medida que se acerca a la cobertura transformadora de Medicare para EsoGuard. También hemos relanzó la cartera de dispositivos médicos de PAVmed bajo un liderazgo experimentado y completó la licencia de nuestra tecnología de imágenes endoscópicas esofágicas de la Universidad de Duke, agregando otro motor de crecimiento potencial a nuestra cartera". Aspectos destacados del cuarto trimestre y de las últimas semanas: PAVmed fortaleció su balance mediante la finalización de una oferta de acciones preferentes Serie D de 30 millones de dólares y una financiación de notas senior garantizadas de 15 millones de dólares. Una parte de los ingresos de estas actividades se utilizó para eliminar todos los valores convertibles previamente en circulación, eliminando un importante exceso de estructura de capital heredada y ampliando la pista de efectivo de la Compañía. Además, la compañía emitió $30 millones en garantías Serie D, que pueden ser exigibles tras la publicación de un borrador de la política de cobertura de CMS para la prueba de ADN esofágico EsoGuard de Lucid. PAVmed relanzó su cartera de dispositivos médicos y nombró al veterano de la industria Joseph Virgilio como director comercial de dispositivos médicos para supervisar el desarrollo y la comercialización de su cartera de dispositivos actual y futura, incluido el dispositivo implantable de acceso vascular intraóseo PortIO y la tecnología de imágenes endoscópicas esofágicas con licencia de la Universidad de Duke. Veris avanzó en su compromiso estratégico con el James Cancer Hospital de la Universidad Estatal de Ohio, con la fase comercial en marcha y la integración total con el sistema de registros médicos electrónicos (EHR) del hospital ya completada. Veris está comprometida con su socio de desarrollo y fabricación de su monitor fisiológico implantable, lo que respalda la presentación prevista de la FDA 510(k) para finales de 2026. Lucid Diagnostics anunció resultados financieros del cuarto trimestre y del año completo 2025 y desarrollos comerciales clave, que incluyen: Reconoció $1.5 millones en ingresos de la prueba de ADN esofágico EsoGuard ® para el 4T25 y procesó 3664 pruebas EsoGuard. Se le otorgó el contrato del Departamento de Asuntos de Veteranos (VA) de EE. UU. para EsoGuard, ampliando el acceso en todo el sistema de atención médica integrado más grande del país que atiende a aproximadamente nueve millones de veteranos. Se anunciaron datos positivos de la mayor experiencia del mundo real reportada sobre detección de precáncer de esófago, evaluando el dispositivo de recolección de células esofágicas EsoGuard y EsoCheck ® de Lucid en casi 12,000 pacientes en riesgo. Resultados financieros: Para los tres meses terminados el 31 de diciembre de 2025, los gastos operativos fueron de aproximadamente $6,9 millones, que incluyen gastos de compensación basados ​​en acciones de $0,3 millones. La pérdida neta GAAP atribuible a los accionistas comunes fue de aproximadamente $1,8 millones, o $(2,05) por acción común sobre una base diluida. Como se muestra a continuación y con el propósito de ilustrar el efecto de la compensación basada en acciones y otros ingresos y gastos no monetarios en los resultados financieros de la Compañía, la pérdida ajustada no GAAP de la Compañía fue de aproximadamente $0,9 millones o $(1,05) por acción ordinaria. PAVmed tenía efectivo y equivalentes de efectivo de $1,5 millones al 31 de diciembre de 2025, en comparación con $1,2 millones al 31 de diciembre de 2024. Los resultados financieros auditados para el año que finalizó el 31 de diciembre de 2025 se presentaron ante la SEC en el Formulario 10-K el 27 de marzo de 2026 y están disponibles en www.pavmed.com o www.sec.gov. Medidas no GAAP de PAVmed Para complementar nuestros resultados financieros presentados de acuerdo con los principios de contabilidad generalmente aceptados (GAAP) de EE. UU., la administración proporciona ciertas medidas financieras no GAAP de los resultados financieros de la Compañía. Estas medidas financieras no GAAP incluyen la pérdida neta antes de intereses, impuestos, depreciación y amortización (EBITDA) y la pérdida ajustada no GAAP, que ajusta aún más el EBITDA por los gastos de compensación basados ​​en acciones, la pérdida por la emisión o modificación de valores convertibles, el cambio periódico en el valor razonable de los valores convertibles y la pérdida por extinción de deuda. Las medidas financieras no GAAP anteriores de EBITDA y pérdida ajustada no GAAP no son términos reconocidos según los US GAAP. Las medidas financieras no GAAP se presentan con la intención de brindar mayor transparencia a la información que utilizamos en nuestro análisis de desempeño financiero y toma de decisiones operativas. Creemos que estas medidas financieras no GAAP brindan información significativa para ayudar a los inversionistas, accionistas y otros lectores de nuestros estados financieros a hacer comparaciones con nuestros resultados financieros históricos y analizar el desempeño subyacente de nuestros resultados de operaciones. Estas medidas financieras no GAAP no pretenden ser, ni deben ser, un sustituto, consideradas superiores, consideradas por separado o como una alternativa a las medidas financieras GAAP más directamente comparables. Se proporcionan medidas financieras no GAAP para mejorar la comprensión general de los lectores sobre nuestros resultados financieros actuales y para proporcionar más información con fines comparativos. La administración cree que las medidas financieras no GAAP brindan información útil a la administración y a los inversionistas al aislar ciertos gastos, ganancias y pérdidas que pueden no ser indicativos de nuestros resultados operativos principales y perspectivas comerciales. Específicamente, las medidas financieras no GAAP incluyen pérdidas ajustadas no GAAP, y su presentación tiene como objetivo ayudar al lector a comprender el efecto de la pérdida en la emisión o modificación de valores convertibles, el cambio periódico en el valor razonable de los valores convertibles, la pérdida por extinción de deuda y la contabilidad correspondiente de los cargos no monetarios sobre el desempeño financiero. Además, la gerencia cree que las medidas financieras no GAAP mejoran la comparabilidad de los resultados con períodos anteriores. Una conciliación con la medida GAAP más directamente comparable de todas las medidas financieras no GAAP incluidas en este comunicado de prensa para los tres meses y el año terminado el 31 de diciembre de 2025 y 2024 es la siguiente: Estado de operaciones consolidado condensado (no auditado) Para los tres meses terminados el 31 de diciembre de Para el año terminado el 31 de diciembre de 2025 2024 2025 2024 (en miles, excepto cantidades por acción) Ingresos $ 52 $ 10 $ 71 $ 2,995 Gastos operativos 6,853 5 198 21,877 47,482 Otros (ingresos) Gastos (4,046) (6 330) Historia completa disponible en Benzinga.com

#STOCKS